|Dr. Arie S. Belldegrun F.A.C.S., FACS, M.D.||Co-Founder & Exec. Chairman||726.91k||N/A||1949|
|Dr. David D. Chang M.D., Ph.D.||Co-Founder, Pres, CEO & Director||1.09M||190.77k||1960|
|Mr. Joshua A. Kazam||Co-Founder & Director||657.16k||N/A||1977|
|Dr. Eric Thomas Schmidt Ph.D.||Chief Financial Officer||655.5k||103.68k||1970|
|Dr. Alison Moore Ph.D.||Chief Technical Officer||743.55k||N/A||1967|
|Mr. Veer Bhavnagri||Gen. Counsel & Compliance Officer||653.37k||1.34M||1983|
|Dr. Rafael G. Amado M.D.||Exec. VP of R&D||910.72k||N/A||1964|
|Ms. Barbra Sasu||Chief Scientific Officer||N/A||N/A||N/A|
|Mr. Stephen Cheng||Chief Information Officer||N/A||N/A||N/A|
|Ms. Christine Cassiano||Chief Communications Officer||N/A||N/A||N/A|
Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell ALL. The company also develops ALLO-501, an anti-CD19 allogeneic CAR T cell product candidate that is in Phase I clinical trial for the treatment of R/R non-Hodgkin lymphoma; and ALLO-501A, which is in Phase I/II clinical trial for the treatment R/R large B-cell lymphoma or transformed follicular lymphoma. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-819, an allogeneic CAR T cell product candidates for the treatment of acute myeloid leukemia; and DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc., as well as clinical trial collaboration agreement with SpringWorks Therapeutics, Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates. The company was incorporated in 2017 and is headquartered in South San Francisco, California.
Allogene Therapeutics, Inc.’s ISS governance QualityScore as of 1 December 2022 is 9. The pillar scores are Audit: 6; Board: 9; Shareholder rights: 8; Compensation: 8.